ClinicalTrials.gg
CompletedNCT00576732Updated May 9, 2014Results posted

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

A Phase 4 interventional study of Placebo and Risperidone high dose in Autistic Disorder and Autism, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 20 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-09.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
134th of 504
96 · median 44
Started
2007
with 17 others
Phase 4
18 of 603
3 open now
Registered
78th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 134th largest by enrollment of the 504 interventional ones that give a count, is one of 18 that started in 2007, is one of 18 in phase 4, and was the 78th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children or adolescents who have autism, and to evaluate the safety and tolerability of the drug for additional 26 weeks after the initial 6-week study period.

Read the detailed description

Autistic Disorder is a condition that develops early in childhood and persists throughout life. Seventy-five percent of children and adolescents with autistic disorder have irritability symptoms such as aggression towards others, deliberate self-injurious behavior, temper tantrums, and quickly changing moods. These symptoms affect their daily functioning such as school performance, interactions with family members and compliance to treatment. Risperidone is an atypical antipsychotic agent that has been recently approved for the treatment of irritability associated with Autistic Disorder in children and adolescents aged 5 to 16 years. The approved dose range is 0.5-3 mg per day. The aim of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) of a lower dose (0.125 mg or 0.175 mg risperidone per day depending on body weight). The study will include three treatment groups. A placebo group, a low dose risperidone group and a higher dose risperidone group (1.25 mg or 1.75mg per day depending on body weight). This phase of the study will be 6 weeks. During the study, neither investigators nor the patients will be told which treatment the patient received. This is called "double blind". The placebo treatment is not expected to be effective. The higher dose group is expected to be effective. At the end of the study, data from the lower dose group will be compared to the placebo group to see if it is effective. Another aim of this study is to evaluate the safety and tolerability of risperidone. At the end of the 6-week double-blind period, patients may enter a 6-month open-label period during which all patients will receive risperidone. During this phase of the study, the doses can be adjusted to a maximum of 1.25 mg or 1.75mg per day depending on body weight. Both investigator and the patient will know what dose the patient is taking. About 93 patients will be randomized. The study will be conducted by investigators from about 15 clinics. Assessments of effectiveness include the Aberrant Behavior Checklist (ABC) subscales including the irritability subscale (ABC-I), the Clinical Global Impression of Change (CGI C); the Clinical Global Impression of Severity (CGI-S); the response rate, and the Compulsions Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY BOCS). Safety evaluations include monitoring of adverse events, physical examinations, clinical laboratory tests, nighttime sleep quality and daytime drowsiness, and extrapyramidal symptoms (EPS) as assessed using the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Rating Scale (BARS) and the Simpson-Angus Scale (SAS). Venous blood samples will be collected for the determination of plasma concentrations of risperidone and 9-hydroxyrisperidone. The study hypotheses are that the higher dose level of risperidone is significantly superior to placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week 6 or early withdrawal) and that the lower dose level of risperidone is significantly superior to placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week 6 or early withdrawal). Double-blind phase: Risperidone oral solutions taken once daily. Depending on body weight patients take 1.25 mL or 1.75 mL of either a 0.1 mg/mL or a 1.0 mg/mL risperidone solution or matching placebo, for 6 weeks. Open-label phase: Medication can be taken once or twice a day. Starting from 0.125mg or 0.175mg per day, drug levels are titrated over 2 weeks to a maximum dose level of 1.25 mg risperidone/day or 1.75 mg /day depending on body weight, for 26 weeks.

03

Conditions studied

  • Autistic Disorder
  • Autism

Browse trials for

Keywords

  • Irritability
  • Risperidone
  • Antipsychotic agent
  • Autism
  • Adolescents
  • Children
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Autistic Disorder (299.00)
  • ABC-I Subscale score of greater than or equal to 18
  • CGI-S of greater than or equal to 4
  • mental age >18 months, body weight of at least 20 kg, seizure-free for at least 6 consecutive months and if on anticonvulsants must be on a dosage that has been stable for at least 4 weeks
  • Medication free for 1 week before the start of the study for all psychotropic drugs, except 4 weeks for fluoxetine and at least 8 weeks for injectable medications
  • Female patients must be premenarchal or sexually abstinent or, if heterosexually active, must practice an effective method of .

Exclusion criteria

Exclusion Criteria:

  • History of prior or current psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's
  • Any history of to risperidone, or its in formulation, or other known drug allergy
  • Patients who received risperidone within 3 months before screening (except p.r.n. use)
  • Patients who did not demonstrate sufficient clinical response to an adequate trial of risperidone treatment in the past (an adequate trial is defined as a period of at least 4 weeks at an adequate dose)
  • Neurologic disorder (e.g., Neuroleptic Malignant Syndrome, seizure disorders that are unstable, seizure activity within the past 6 months)
  • History of alcohol or substance dependence within 3 months of screening
  • Female subject who is pregnant (positive beta-HCG) or breast feeding
  • Patients with existing moderate or severe EPS or history of tardive dyskinesia
  • Patients who have received an experimental drug or used an experimental medical device within 3 months before the planned start of treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    001

    Risperidone low dose Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks

    Drug: Risperidone low dose

  • Experimental
    002

    Risperidone high dose Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks

    Drug: Risperidone high dose

  • Placebo comparator
    003

    Placebo Oral solution qd or bid for 6 weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Oral solution qd or bid for 6 weeks

  • DrugRisperidone high dose

    Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks

  • DrugRisperidone low dose

    Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale

    Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Number of Participants Who Had at Least 25% Improvement in ABC-I

    ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).

    Time frame: 6 weeks

  2. Change in Clinical Global Impression Severity (CGI-S)

    Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1="not ill", 2="very mild", 3="mild", 4="moderate", 5="marked", 6="severe", 7="extremely severe").

    Time frame: Baseline and 6 weeks

  3. Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.

    Investigator impression of change over time from double-blind baseline on a 7-point scale (1="very much improved", 2="much improved", 3="minimally improved", 4="no change", 5="minimally worse", 6="much worse", 7="very much worse").

    Time frame: 6 weeks

  4. Change in Fasting Glucose (mg/dL) at 6 Weeks

    Time frame: Baseline and 6 weeks

  5. Change in Insulin Resistance (IR) at 6 Weeks

    Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.

    Time frame: Baseline and 6 weeks

  6. Change in Fasting Glucose (mg/dL) at 6 Months

    Time frame: Baseline and 6 months

  7. Change in Insulin Resistance (IR) at 6 Months

    Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.

    Time frame: Baseline and 6 months

07

Results

Posted Sep 28, 2010

Participant flow

DOUBLE BLIND
Participant flow — DOUBLE BLIND
MilestonePlaceboRisperidone Low DoseRisperidone High DosePlacebo/RISRis Low Dose/RISRis High Dose/RIS
Started353031000
Completed272525000
Not completed856000
Withdrew: Adverse event001000
Withdrew: Lost to follow-up011000
Withdrew: Withdrawal by subject113000
Withdrew: Other021000
Withdrew: Lack of efficacy610000
Withdrew: Protocol violation100000
OPEN LABEL
Participant flow — OPEN LABEL
MilestonePlaceboRisperidone Low DoseRisperidone High DosePlacebo/RISRis Low Dose/RISRis High Dose/RIS
Started000302425
Completed000192017
Not completed0001148
Withdrew: Adverse event000401
Withdrew: Lost to follow-up000211
Withdrew: Withdrawal by subject000101
Withdrew: Other000002
Withdrew: Lack of efficacy000223
Withdrew: Protocol violation000210

Outcome measures

PrimaryChange in Aberrant Behavior Checklist Irritability (ABC-I) Subscale

Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale
units on a scalePlaceboRisperidone Low DoseRisperidone High Dose
Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale-3.5 ± 10.67-7.4 ± 8.12-12.4 ± 6.52
Statistical analysis
  • Placebo vs Risperidone High Dose · ANCOVA · p = <0.001 (Type I error is preserved by the step down procedure, no multiple comparison adjustment is needed. A priori threshold for statistical significance was 0.05.) · Mean difference (final values): -7.9 · 95% CI -12.19 to -3.52Mean difference is change in Risperidone high dose arm minus change in placebo arm.
  • Placebo vs Risperidone Low Dose · ANCOVA · p = 0.164 (Type I error is preserved by the step down procedure, no multiple comparison adjustment is needed. A priori threshold for statistical significance was 0.05.) · Mean difference (final values): -3.0 · 95% CI -7.36 to 1.27Mean difference is change in Risperidone low dose arm minus change in placebo arm.
SecondaryNumber of Participants Who Had at Least 25% Improvement in ABC-I

ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).

Time frame:
6 weeks
Reported as:
Number · participants
Number of Participants Who Had at Least 25% Improvement in ABC-I
participantsPlaceboRisperidone Low DoseRisperidone High Dose
Number of Participants Who Had at Least 25% Improvement in ABC-I141524
Statistical analysis
  • Placebo vs Risperidone High Dose · Cochran-Mantel-Haenszel · p = 0.004 (P-value is not adjusted for multiple comparisons.)Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.
  • Placebo vs Risperidone Low Dose · Cochran-Mantel-Haenszel · p = 0.817 (P-value is not adjusted for multiple comparisons.)Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.
SecondaryChange in Clinical Global Impression Severity (CGI-S)

Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1="not ill", 2="very mild", 3="mild", 4="moderate", 5="marked", 6="severe", 7="extremely severe").

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change in Clinical Global Impression Severity (CGI-S)
units on a scalePlaceboRisperidone Low DoseRisperidone High Dose
Change in Clinical Global Impression Severity (CGI-S)-0.3 ± 0.79-0.4 ± 0.73-1.0 ± 0.78
Statistical analysis
  • Placebo vs Risperidone High Dose · ANCOVA · p = <0.001 (P-value is not adjusted for multiple comparisons.) · Mean difference (final values): -0.7 · 95% CI -1.02 to -0.33Mean difference is change in Risperidone high dose arm minus change in placebo arm.
  • Placebo vs Risperidone Low Dose · ANCOVA · p = 0.769 (P-value is not adjusted for multiple comparisons.) · Mean difference (final values): -0.1 · 95% CI -0.39 to 0.29Mean difference is change in Risperidone low dose arm minus change in placebo arm.
SecondaryNumber of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.

Investigator impression of change over time from double-blind baseline on a 7-point scale (1="very much improved", 2="much improved", 3="minimally improved", 4="no change", 5="minimally worse", 6="much worse", 7="very much worse").

Time frame:
6 weeks
Reported as:
Number · participants
Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.
participantsPlaceboRisperidone Low DoseRisperidone High Dose
Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.5519
Statistical analysis
  • Placebo vs Risperidone High Dose · Cochran-Mantel-Haenszel · p = <0.001 (P-value is not adjusted for multiple comparisons.)Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.
  • Placebo vs Risperidone Low Dose · Cochran-Mantel-Haenszel · p = 0.985 (P-value is not adjusted for multiple comparisons.)Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.
SecondaryChange in Fasting Glucose (mg/dL) at 6 Weeks
Time frame:
Baseline and 6 weeks
Reported as:
Mean · mg/dL
Change in Fasting Glucose (mg/dL) at 6 Weeks
mg/dLPlaceboRisperidone Low DoseRisperidone High Dose
Change in Fasting Glucose (mg/dL) at 6 Weeks-0.4 ± 8.20-0.1 ± 8.81-0.3 ± 9.74
SecondaryChange in Insulin Resistance (IR) at 6 Weeks

Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change in Insulin Resistance (IR) at 6 Weeks
units on a scalePlaceboRisperidone Low DoseRisperidone High Dose
Change in Insulin Resistance (IR) at 6 Weeks0.36 (-0.34 to 1.07)-0.10 (-0.76 to 0.55)0.45 (-0.18 to 1.08)
SecondaryChange in Fasting Glucose (mg/dL) at 6 Months
Time frame:
Baseline and 6 months
Reported as:
Mean · mg/dL
Change in Fasting Glucose (mg/dL) at 6 Months
mg/dLPlacebo/RISRis Low Dose/RISRis High Dose/RIS
Change in Fasting Glucose (mg/dL) at 6 Months4.0 ± 12.273.5 ± 12.262.3 ± 8.70
SecondaryChange in Insulin Resistance (IR) at 6 Months

Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.

Time frame:
Baseline and 6 months
Reported as:
Mean · units on a scale
Change in Insulin Resistance (IR) at 6 Months
units on a scalePlacebo/RISRis Low Dose/RISRis High Dose/RIS
Change in Insulin Resistance (IR) at 6 Months0.09 ± 2.670.36 ± 0.890.75 ± 0.91

Adverse events

Collected over Double-blind period: 6 weeks. Open-label period: 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/35 (2.9%)20/35 (57.1%)
Risperidone Low Dose—0/30 (0%)12/30 (40%)
Risperidone High Dose—0/31 (0%)27/31 (87.1%)
Open-label Risperidone—1/79 (1.3%)39/79 (49.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboRisperidone Low DoseRisperidone High DoseOpen-label Risperidone
AggressionPsychiatric disorders1/350/300/310/79
HydroceleCongenital, familial and genetic disorders0/350/300/311/79
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboRisperidone Low DoseRisperidone High DoseOpen-label Risperidone
Increased appetiteMetabolism and nutrition disorders2/355/3011/319/79
SedationNervous system disorders0/351/308/316/79
SomnolenceNervous system disorders1/350/307/314/79
NasopharyngitisInfections and infestations2/352/304/315/79
Weight increasedInvestigations2/353/304/317/79
HeadacheNervous system disorders4/352/302/314/79
Upper respiratory tract infectionInfections and infestations1/351/303/316/79
VomitingGastrointestinal disorders2/352/302/317/79
Abdominal discomfortGastrointestinal disorders3/350/300/312/79
PyrexiaGeneral disorders0/350/302/316/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboRisperidone Low DoseRisperidone High DoseTotal
<=18 years35303196
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)PlaceboRisperidone Low DoseRisperidone High DoseTotal
Mean8.6 ± 2.5710.2 ± 3.429.3 ± 3.119.3 ± 3.07
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisperidone Low DoseRisperidone High DoseTotal
Female45312
Male31252884
Region of Enrollment
Region of Enrollment(participants)PlaceboRisperidone Low DoseRisperidone High DoseTotal
United States of America35303196
Age Categorical
Age Categorical(participants)PlaceboRisperidone Low DoseRisperidone High DoseTotal
<12 years30202474
>=12 years510722
08

Study locations

20 sites
  • Dothan, Alabama, United States
  • Phoenix, Arizona, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Boca Raton, Florida, United States
  • Miami, Florida, United States
  • Smyrna, Georgia, United States
  • Hoffman Estates, Illinois, United States
  • Naperville, Illinois, United States
  • Lake Charles, Louisiana, United States
  • Bronx, New York, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Fairfax, Virginia, United States
  • Portsmouth, Virginia, United States
09

References and documents

Publications

  • Kent JM, Hough D, Singh J, Karcher K, Pandina G. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2013 Dec;23(10):676-86. doi: 10.1089/cap.2012.0058. PubMed 24350813 ↗
  • Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, Singh J, Hough D. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013 Aug;43(8):1773-83. doi: 10.1007/s10803-012-1723-5. PubMed 23212807 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2007
First posted
Dec 19, 2007
Start
Dec 2007
Primary completionActual
Sep 2009
CompletionActual
Mar 2010
Results first posted
Sep 28, 2010
Last update
May 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00576732
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Dec 2007
Primary completion
Sep 2009
Completion
Mar 2010
Results posted
Sep 28, 2010
Last update
May 9, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion